Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on September 4, 2009
Japanese Journal of Clinical Oncology 2009 39(12):847-849; doi:10.1093/jjco/hyp100
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/12/847    most recent
hyp100v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kono, T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kono, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

Preventive Effect of Goshajinkigan on Peripheral Neurotoxicity of FOLFOX Therapy: A Placebo-controlled Double-blind Randomized Phase II Study (the GONE Study)

Toru Kono1{dagger}, Hideyuki Mishima2,{dagger}, Mitsuo Shimada3, Satoshi Morita4, Junichi Sakamoto5 for the GONE investigators

1 Division of Gastroenterologic and General Surgery, Department of Surgery, Asahikawa Medical College, Hokkaido
2 Department of Gastroenterological Surgery, Osaka National Hospital, Osaka
3 Department of Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School of Medicine, Tokushima
4 Department of Biostatistics and Epidemiology, Yokohama City University Medical Center, Kanagawa
5 Program in Health and Community Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

For reprints and all correspondence: Toru Kono, Division of Gastroenterologic and General Surgery, Department of Surgery, Asahikawa Medical College, 2-1, Midorigaoka-Higashi, Asahikawa, Hokkaido 078-8510, Japan. E-mail: kono{at}asahikawa-med.ac.jp

Received May 25, 2009; accepted July 22, 2009

We conducted a controlled double-blind randomized study in patients with advanced/recurrent colorectal cancer to investigate the efficacy of Goshajinkigan (GJG) for peripheral neurotoxicity induced by FOLFOX therapy. The primary endpoint is the incidence of peripheral neurotoxicity ≥Grade 2 after eight cycles of chemotherapy. The secondary endpoints are the incidence of peripheral neurotoxicity of each grade after each cycle, the psychometric properties of the FACT/GOG-Ntx, time to occurrence of neurotoxicity, time to treatment failure, progression-free survival, response rate and toxicity. Eighty patients are required in the study (40 patients per group).

Key Words: colorectal cancer • Japanese herbal medicine • oxaliplatin • Goshajinkigan • neurotoxicity

{dagger} These authors contributed equally to this work.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.